Plain-English translation of NCT05003934 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing cultured allogeneic adult umbilical cord derived mesenchymal stem cells — cells grown in a lab from donated umbilical cord tissue — as a treatment for rheumatoid arthritis. You would receive a single intravenous infusion (injection into your vein) containing 100 million of these cells. The trial will track your safety and how well the treatment works over four years.
Early research suggests that stem cell treatment may be safe and effective for rheumatoid arthritis, but more careful testing in patients is needed to confirm this and ensure there are no unexpected side effects.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic once before treatment for baseline tests and lab work. Then you would receive a single intravenous infusion of the stem cells, which is an outpatient procedure. After that, you would return for follow-up visits at 1 month, 6 months, 12 months, 24 months, 36 months, and 48 months after your infusion to have blood tests, exams, and assessments of your arthritis symptoms.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
Antigua and Barbuda
Argentina
Phase
Safety & dosing
Sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Enrollment target
~20 participants
Started
November 2021
Primary completion
September 2026
Last updated on clinicaltrials.gov in April 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.